OpenEvidence is the most widely used medical AI platform in the world.

In just over a year, our usage has grown to >65% of US clinicians via product-led word of mouth adoption. We are a $12B company with a 30 person engineering team from MIT, Harvard, and Stanford. We believe world-changing products come from a small group of exceptional, autonomous builders, organized along focused objectives and empowered to take individual ownership and run fast. We are now bringing OpenEvidence to clinicians and health workers in low- and middle-income countries, where access to high-quality medical expertise is scarcest and the stakes are highest. Doing that responsibly means proving, to a credible standard, that it is accurate, safe, and useful at the point of care in those settings. If you are a world-class clinician-scientist who wants to own that proof and shape how the best medical AI in the world is validated and adapted for the places that need it most, we want to talk.

Culture

We believe work is something that should be engaged with at a world-class level. Building 0->1 and scaling 1->1000 are professional sports, and uncompromising excellence is the bar. We believe building things that haven't existed is only possible with end to end ownership. We don't have separate project managers or study coordinators; you are responsible for defining what we need to prove, to what standard, and with whom, and for driving it to a result. Important things are accomplished when an individual decides to accomplish them.

We believe that work should be hard. We believe good work is precise and intentional. Doing something a certain way just because that's how others in digital health are doing it guarantees mediocrity. We believe the quality of the product is paramount and the smallest details matter most, and nowhere more than in the gap between benchmark performance and real-world clinical safety. At the same time, velocity is essential. The best clinician-scientists know how to jump right to the hardest part of the problem and focus on patient safety. We believe your job is to complete and announce important evaluations and demonstrate their impact.

Who are you?

If you are looking to run studies someone else designed, this job is not for you. If you are looking to write papers as an end in itself, this job is not for you. If you are looking to lean in and get your hands dirty, bruised, and bloody building the clinical evidence base for medical AI in low-resource settings from nothing, shaping the safeguards at the point of care, and impacting hundreds of millions of lives, this job might be for you.

The ideal candidate is a brilliant builder who is also a practicing clinician. They are smart, ambitious, scrappy, autonomous, precise, motivated, hard-working, and low-ego. They have medical training and clinical practice (MD, GP, MBBS, or equivalent) with direct experience delivering care, and they reason fluidly from how diagnosis, triage, treatment, and referral actually happen at the bedside. They have a concrete, on-the-ground understanding of clinical and care-delivery workflows in LMICs and what those workflows mean for how AI tools must be designed and evaluated. Does that sound rare? It is rare, and we would like to find them.

The role

You will own the clinical research and evaluation agenda for OpenEvidence in global health. You will design the clinical evaluations and validation frameworks that establish how OpenEvidence performs in LMIC contexts, covering accuracy, safety, multilingual performance, and real-world conditions, working side by side with our research, evaluation, and product teams. You will develop theories of change and outcome metrics that connect OpenEvidence's capabilities to care quality, health-worker performance, and patient outcomes, and you will help shape the safeguards that make the product safe and usable at the point of care. You will stay grounded in how care is actually delivered in low-resource settings and translate that into product improvements, not just evaluations. You will join a small, tight-knit global health team: you lead on this domain, but you should expect to roll up your sleeves on adjacent workstreams, help set overall strategy, and be a thought partner to colleagues working on other parts of the health system. You will spend roughly 25% of your time at research and partner sites.

Skillsets

Specific skillsets are secondary to the clinician-builder profile above, but some important spikes for different facets of this work are:

Clinical AI evaluation

You have direct experience evaluating or validating clinical AI/ML tools, and you understand the gap between benchmark performance and real-world clinical safety.
You have deep expertise in clinical research and evidence generation for digital health or AI tools, with a clear view of what counts as credible evidence for safety and effectiveness. Evaluation and quantitative proof are first-class citizens to you.

Regulatory and normative landscape

You have a strong command of the regulatory and normative landscape for clinical AI, including WHO processes, national regulatory authorities in LMICs, and research ethics.

Research partnerships

You have a track record of building research partnerships with academic and in-country researchers, and you treat local partners as scientific collaborators rather than data-collection sites.
You may have worked with philanthropic funders on evidence generation or research strategy.

Industry and field experience

You might have experience at a healthtech or AI company in clinical validation, clinical quality, or medical affairs, or a publication record in digital health, clinical AI evaluation, or implementation science.
You might have direct clinical experience in a low- or middle-income country, including with humanitarian or global-health delivery organizations.

We work in person in Miami and SF, and this role travels regularly (~25%) to research and partner sites. We believe in creating an environment that optimizes for focus and productivity, including providing meals, transport, and anything else you need to move quickly.

About the company

OpenEvidence builds AI-driven clinical decision support tools that help healthcare professionals make better choices at the point of care. It creates AI models and interfaces that integrate with existing platforms (notably through Mayo Clinic Platform Accelerate) and partner ecosystems like Elsevier Health to power products such as ClinicalKey AI. Clinicians use these tools inside their regular clinical workflows, with AI assisting by analyzing medical literature, guidelines, and patient data to suggest evidence-based options.

Company Size

51-200

Company Stage

Late Stage VC

Total Funding

$1B

Headquarters

Miami, Florida

Founded

2022

Get referred to OpenEvidence

See people who can refer or advise you

Simplify's Take

What believers are saying

September 2026 funding valued OpenEvidence at $15 billion, with hospital systems participating.
September 2026 Anthropic partnership expands free distribution across nearly 100 countries.
September 2026 audits found zero fabricated citations across 4,979 references, strengthening trust.

What critics are saying

OpenEvidence faces Doximity trade-secret litigation in federal court, with contempt threats in September 2026.
April 2026 EU and UK withdrawal shows regulation can instantly cut off markets.
Anthropic, OpenAI, and incumbents like UpToDate now attack its core physician workflow category.

What makes OpenEvidence unique

OpenEvidence owns point-of-care physician workflows, now embedded at MSK, Penn, and UTMB in 2026.
Its September 2026 model family splits speed and depth: Osler, Sackett, Snow, Darwin.
NCCN, ASCO, and OncoKB integrations create a defensible oncology knowledge moat.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Meal Benefits

Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

↑ 2%

1 year growth

↑ 15%

2 year growth

↑ 0%

Business Insider

Sep 24th, 2026

The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round.

The 'ChatGPT for doctors,' OpenEvidence, was valued at $15 billion in a new funding round. Sep 24, 2026, 10:35 AM PT OpenEvidence, an AI search engine for doctors, is the latest AI darling to raise back-to-back funding rounds. The company recently raised $250 million in investment from hospital systems and Andreessen Horowitz, valuing OpenEvidence at $15 billion, according to people familiar with the matter. In January, OpenEvidence raised a new round of funding that valued the company at $12 billion. OpenEvidence could be open to an M&A deal that includes access to compute, which could become scarcer in the future if rising anti-AI sentiment curbs data center expansion, according to a person familiar with the matter. It could not be verified if the company has M&A interest from possible acquirers, and OpenEvidence may prefer to remain independent. Based in Miami, OpenEvidence has raised over $1 billion in the past year, from investors including Thrive Capital, DST, GV, Kleiner Perkins, and Sequoia Capital. The startup has called its AI-powered search engine "the fastest-growing application for physicians in history." The new funding round comes as OpenAI, Anthropic, and other AI giants make a bigger push into healthcare. Instead of just providing the models that power other companies' products, they're increasingly building healthcare tools of their own. As an acquisition, OpenEvidence could offer a shortcut. It already has doctors using its product, experience handling sensitive medical information, and a foothold in a massive market that AI companies increasingly want to own. Founded in 2022, OpenEvidence has already become widely used by medical professionals, with more than two-thirds of U.S. doctors relying on the AI product for its diagnostic and treatment advice. OpenEvidence maintains relationships with several of the largest technology companies and counts Nvidia as an investor. Anthropic announced a partnership with the company this week. OpenEvidence integrates with both Google and Microsoft's AI tools. There has been a wave of major AI M&A lately, with Nvidia buying HuggingFace for nearly $13 billion and Stripe buying OpenRouter for around $8 billion, as the race to acquire AI talent remains strong.

Digital Health Wire

Sep 24th, 2026

OpenEvidence raises $250M at $15B valuation, quietly pivots to oncology drug development

OpenEvidence has raised $250 million at a $15 billion valuation, led by a16z and Byers Capital, marking a notable shift from its previous trajectory. The company had floated a $20 billion valuation in July but settled lower in September. The funding announcement coincided with news that OpenEvidence is pivoting into drug development. CEO Daniel Nadler told Forbes the company plans to develop oncology therapies, with its first drug entering clinical trials before year-end and three to five additional candidates next year, focusing on rare cancers. The company also announced a partnership with Memorial Sloan Kettering, integrating its platform into MSK's Epic workflows and distributing MSK's OncoKB database to clinicians. Competition is intensifying, with Doximity reporting AI search queries up 25% quarter-over-quarter.

The Straits Times

Sep 22nd, 2026

Anthropic, OpenEvidence partner to bring medical AI worldwide.

Anthropic, OpenEvidence partner to bring medical AI worldwide. Published Sep 23, 2026, 06:35 AM Updated Sep 23, 2026, 06:35 AM Artificial intelligence startup Anthropic and medical knowledge platform OpenEvidence are collaborating to bring AI-powered clinical decision support to physicians in regions without access to the technology, the companies said on Sept 22. OpenEvidence answers doctors' questions by drawing on peer-reviewed medical research and treatment guidelines. The platform is free to clinicians in the United States and Europe. The new initiative is a specialised version available to healthcare providers for free in dozens of low- and middle-income countries where limited access to medical literature, specialist expertise and continuing medical education can impair patient care. Healthcare systems worldwide are exploring whether generative AI can help address shortages of physicians and specialists. Supporters argue that AI tools can help clinicians quickly navigate vast amounts of medical information, while critics caution that systems trained primarily on data from high-income countries may not reflect local practice conditions. The initiative is being rolled out in about 100 countries, including Uganda, Angola, Sudan, Haiti, and Mongolia, according to a list provided by OpenEvidence. "Access to medical knowledge shouldn't depend on geography," OpenEvidence founder Daniel Nadler said. Reuters reported last week that Anthropic had built a lab to do physical biology work as it pushes its artificial intelligence ambitions into drug science and as fears of AI's reach grip the public, with some executives and lawmakers calling for a slowdown in development.

Yahoo Finance

Sep 22nd, 2026

UTMB integrates OpenEvidence AI platform into clinical workflows, reaching over 50% physician adoption

The University of Texas Medical Branch has integrated OpenEvidence's AI platform directly into its electronic health record system, enabling clinicians to access cited medical evidence within their existing workflows. The integration, launched in March, allows UTMB physicians to ask clinical questions in natural language and receive responses with citations to medical literature and guidelines. Since launch, adoption has grown significantly, with more than half of UTMB clinicians now actively using OpenEvidence for clinical decision support. Clinicians access the platform using standard UTMB credentials without switching between applications or creating separate accounts. The integration is particularly valuable for UTMB's network, which spans four hospital campuses and more than 100 clinics across Southeast Texas. Peter McCaffrey, UTMB's chief digital and AI officer, said the implementation demonstrates that removing friction and placing useful AI tools where clinicians work drives adoption.

FinancialContent

Sep 15th, 2026

OpenEvidence and Penn Medicine partner to advance medical intelligence for Global Health.

OpenEvidence and Penn Medicine partner to advance medical intelligence for Global Health. September 15, 2026 at 10:00 AM EDT i This article is third-party content and does not represent the views of this site. Tamar Securities, LLC make no guarantees regarding its accuracy or completeness. The partnership deploys OpenEvidence to clinicians at Penn Medicine and expands global access to high quality clinical decision-making, including through the Botswana-UPenn Partnership, advancing a shared commitment to global health and AI-enabled clinical decision support in low- and middle-income countries. OpenEvidence, the most widely used medical AI and clinical decision-making tool among U.S. physicians, and Penn Medicine today announced a global partnership to bring AI-powered clinical decision support to Penn Medicine's more than 10,000 clinicians across its seven-hospital U.S. health system. That clinical decision support will also extend to low and middle income countries through the Botswana-UPenn Partnership (BUP). Building on Penn Medicine's deep cooperation with the healthcare sector in Botswana, the agreement with OpenEvidence enables Penn Medicine teams to design a tool from the ground up that is built to support the particular considerations of practicing in the region. OpenEvidence's tools will be accessible to clinicians within the campuses of Penn Medicine and the Botswana-UPenn Partnership, bringing personalized, evidence-based insights - drawn directly from both available medical literature and information pulled directly from the electronic health record - right to Penn's clinicians with the assistance of AI. The idea is to have the right evidence, for the right patient, at the exact right time, all embedded within workflow. "OpenEvidence was founded on the belief that the best available medical evidence should reach every clinician, not only those working inside the world's best resourced hospitals," said Travis Zack, MD, PhD, Chief Medical Officer at OpenEvidence. "Working with academic partners like Penn Medicine, we're building and rigorously evaluating tools for the varied conditions under which most of the world actually practices medicine." "At Penn Medicine, our mission in pursuit of clinical excellence very much includes efforts to extend it to all areas where it can have the greatest impact," said Srinath Adusumalli, MD, MSHP, MBMI, Vice President and Chief Health Information Officer and a cardiologist at the University of Pennsylvania Health System. "A partnership like this gives our clinicians, here at home and elsewhere, the ability to instantly surface the best available medical evidence in the context of the patient in front of them." Penn Medicine places a special focus on underserved communities, and Adusumalli expressed that integrating AI into more Penn Medicine programs, such as the existing clinical decision support program Penn Pathways, electronic consultation programs, as well as brick and mortar and virtual care programs, could expand access to specialized care in meaningful ways. That includes the 25-year-old Botswana-UPenn Partnership, one of the longest-running academic health partnerships in sub-Saharan Africa. Working alongside the University of Botswana and Government of Botswana Ministry of Health, BUP has supported the training of Botswana's clinicians and researchers, helped establish postgraduate medical education programs, and conducted research on HIV/AIDS, oncology, and population health. "Building a customized set of tools in direct partnership with BUP clinicians and partners reflects a shared conviction that effective clinical AI will be shaped by local expertise and adapted for the conditions they practice in," said Farouk Dako, MD, MPH, Director of the Botswana-UPenn Partnership and Strategic Advisor for Academic Partnerships at the University of Pennsylvania Perelman School of Medicine Center for Global Health. "This collaboration offers a model for extending Penn Medicine's resources and expertise to lower-resource settings through sustainable partnerships." About Penn Medicine Penn Medicine is a world leader in academic medicine, comprising the University of Pennsylvania Health System and the Perelman School of Medicine. Home to more than 49,000 team members, Penn Medicine treats nearly half a million emergency patients annually across seven hospitals in Pennsylvania and New Jersey. Through the Botswana-UPenn Partnership, Penn has worked in Botswana since 2001, employing approximately 120 full-time clinical and research staff to build sustainable healthcare capacity in sub-Saharan Africa. Learn more at pennmedicine.org. About OpenEvidence OpenEvidence is the most popular AI for doctors in the United States. According to independent studies, more American physicians use OpenEvidence than all other AI platforms combined. OpenEvidence is trusted by millions of verified U.S. healthcare professionals making high-stakes clinical decisions at the point of care, with evidence that is sourced, cited, and grounded in peer-reviewed medical literature. Founded with the mission to organize and expand the world's collective medical knowledge, OpenEvidence is now used daily, on average, by the majority of physicians in the United States. OpenEvidence is free for all verified U.S. clinicians. Learn more at openevidence.com. Contacts. Report this content If you believe this article contains misleading, harmful, or spam content, please let Tamar Securities, LLC know.

OpenEvidence

Clinical Lead - Beneficial Deployments

About the job